XEOMIN® Safety | Pediatric Patients with Upper Limb Spasticity

Upper Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy

Demonstrated Safety in Pediatric Patients With Upper Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy1

Table displaying the most common adverse reactions affecting greater than or equal to 2 percent of patients treated with XEOMIN.

Reference

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2020.